References
- von Wasielewski R, Mengel M, Fischer R, et al. Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am J Pathol 1997; 151: 1123–1130
- Stein H, Hummel M, Dürkop H, Foss H D, Herbst H. Biology of Hodgkin's disease. The Lymphomas, G P Canellos, T A Lister, J L Sklar. W. B. Saunders Company, Philadelphia 1998; 287–305, Chapter Fifteen
- McLaughlin P, Grillo-Lopez A J, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
- Coiffier B, Haioun C, Ketterer N, et al. Rituximab (Anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 1927–1932